Zoetis (NYSE:ZTS – Get Rating) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a research report issued to clients and investors on Thursday.
Several other research firms have also recently commented on ZTS. William Blair restated an "outperform" rating on shares of Zoetis in a research note on Friday, August 5th. The Goldman Sachs Group reduced their price objective on Zoetis from $208.00 to $202.00 and set a "buy" rating for the company in a report on Thursday, July 21st. Piper Sandler started coverage on shares of Zoetis in a research note on Monday, July 11th. They issued an "overweight" rating and a $205.00 price objective on the stock. Finally, Stifel Nicolaus reduced their target price on shares of Zoetis from $275.00 to $225.00 and set a "buy" rating on the stock in a report on Friday, June 24th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $224.00.
Get Zoetis alerts:Zoetis Price Performance
Shares of NYSE ZTS opened at $148.29 on Thursday. The firm has a market capitalization of $69.42 billion, a PE ratio of 33.63, a price-to-earnings-growth ratio of 2.66 and a beta of 0.77. Zoetis has a fifty-two week low of $147.77 and a fifty-two week high of $249.27. The company has a debt-to-equity ratio of 1.14, a quick ratio of 1.46 and a current ratio of 2.18. The stock's 50-day simple moving average is $164.42 and its 200-day simple moving average is $172.01.
Zoetis (NYSE:ZTS – Get Rating) last announced its quarterly earnings results on Thursday, August 4th. The company reported $1.20 earnings per share for the quarter, missing analysts' consensus estimates of $1.22 by ($0.02). Zoetis had a net margin of 26.14% and a return on equity of 49.03%. The company had revenue of $2.10 billion during the quarter, compared to analysts' expectations of $2.03 billion. During the same period last year, the firm earned $1.19 earnings per share. Zoetis's revenue was up 7.8% on a year-over-year basis. As a group, equities research analysts forecast that Zoetis will post 5.01 EPS for the current fiscal year.Insider Transactions at Zoetis
In other news, EVP Roxanne Lagano sold 2,167 shares of the firm's stock in a transaction on Friday, July 22nd. The stock was sold at an average price of $180.26, for a total value of $390,623.42. Following the transaction, the executive vice president now directly owns 23,687 shares in the company, valued at approximately $4,269,818.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Kristin C. Peck sold 9,689 shares of the business's stock in a transaction that occurred on Thursday, July 21st. The stock was sold at an average price of $180.00, for a total transaction of $1,744,020.00. Following the completion of the sale, the chief executive officer now owns 39,743 shares in the company, valued at $7,153,740. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Roxanne Lagano sold 2,167 shares of the business's stock in a transaction that occurred on Friday, July 22nd. The shares were sold at an average price of $180.26, for a total value of $390,623.42. Following the completion of the sale, the executive vice president now owns 23,687 shares of the company's stock, valued at $4,269,818.62. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 12,167 shares of company stock worth $2,190,623. Company insiders own 0.12% of the company's stock.
Institutional Investors Weigh In On Zoetis
Institutional investors and hedge funds have recently made changes to their positions in the business. Horizon Investments LLC raised its position in Zoetis by 5.5% in the 4th quarter. Horizon Investments LLC now owns 9,113 shares of the company's stock worth $2,220,000 after purchasing an additional 477 shares during the period. Resources Management Corp CT ADV raised its holdings in shares of Zoetis by 18.7% during the first quarter. Resources Management Corp CT ADV now owns 3,112 shares of the company's stock valued at $587,000 after purchasing an additional 491 shares during the last quarter. Raymond James Financial Services Advisors Inc. increased its holdings in Zoetis by 4.5% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 151,858 shares of the company's stock valued at $28,643,000 after buying an additional 6,593 shares during the last quarter. Revolve Wealth Partners LLC boosted its position in shares of Zoetis by 6.3% in the first quarter. Revolve Wealth Partners LLC now owns 1,153 shares of the company's stock worth $217,000 after purchasing an additional 68 shares during the period. Finally, Elk River Wealth Management LLC boosted its position in shares of Zoetis by 22.6% during the first quarter. Elk River Wealth Management LLC now owns 30,672 shares of the company's stock worth $5,784,000 after acquiring an additional 5,651 shares during the last quarter. Institutional investors and hedge funds own 91.05% of the company's stock.
About Zoetis
(Get Rating)
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Articles
- Get a free copy of the StockNews.com research report on Zoetis (ZTS)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Let Paychex Stock Work Hard For You
- Declining Profits Challenge the CarMax Value Proposition
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.